NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-CA-21-115 from the NIH Guide for Grants and Contracts
Notice NOT-AT-21-018 from the NIH Guide for Grants and Contracts
Notice NOT-AT-21-017 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-025 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-021 from the NIH Guide for Grants and Contracts
Notice NOT-HD-21-043 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-185 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-024 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-21-026 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs). The DDRCCs are part of an integrated program of digestive and liver diseases research support provided by the NIDDK. The purpose of this Centers program is to bring together basic and clinical investigators as a means to enhance communication, collaboration, and effectiveness of ongoing research related to digestive and/or liver diseases within the NIDDK's mission. DDRCCs are based on the core concept, whereby shared resources aimed at fostering productivity, synergy, and new research ideas among the funded investigators are supported in a cost-effective manner. Each proposed DDRCC must be organized around a central theme that reflects the focus of the digestive or liver diseases research of the Center members. The central theme must be within the primary mission ofthe NIDDK, and not thematic areas for which other NIH Institutes or Centers are considered the primary source of NIH funding.
Funding Opportunity PAR-21-332 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter term outcomes such as weight loss and diabetes. The goal of this FOA is to support proof of concept studies for feasibility and exploratory development. Feasibility must not have already been developed in the literature or with preliminary data. While unpublished data are not permitted, references and data from widely available preprints that have a Digital Object Identifier (DOI) are acceptable. Investigators who have generated unpublished preliminary data should submit a proposal to companion R01.
Funding Opportunity PAR-21-331 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter-term outcomes such as weight loss and diabetes.
Funding Opportunity RFA-OH-22-004 from the NIH Guide for Grants and Contracts. To help address the Zadroga Act research mandate (Public Law 111347, as amended by Public Laws 114113 and 11659), as supported by the World Trade Center (WTC) Health Program in consultation with the WTC Health Program Scientific/Technical Advisory Committee, NIOSH is soliciting applications for scientifically rigorous research (42 U.S.C. 300mm51) among enrolled certified-eligible WTC survivors and similarly exposed populations in New York City in Manhattan between Houston Street and 14th Street and in Brooklyn to help answer critical questions about: Physical and mental health conditions that may be related to the September 11, 2001, terrorist attacks; Diagnosing WTC-related health conditions for which there has been diagnostic uncertainty; and Treating WTC-related health conditions for which there has been treatment uncertainty.
Funding Opportunity PAR-22-022 from the NIH Guide for Grants and Contracts. The purpose of the NINDS Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support of a cohort of new and talented, independent investigators from diverse backgrounds conducting AD/ADRD research. The program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see NIHs Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees establish independent research programs in the AD/ADRD field. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.
Funding Opportunity PAR-21-322 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.
Funding Opportunity PAR-21-323 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.
Funding Opportunity PAR-21-324 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.
Longitudinal Single Cell Characterization of ADRD Postmortem Tissue (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-22-029 from the NIH Guide for Grants and Contracts. This FOA aims to address three major goals. The first is to utilize single-cell(-nuc) technologies to characterize the changes to cell identity, number, and/or morphology within a defined brain region, the hippocampus, from subjects experiencing mild cognitive impairment (MCI). Specifically, applicants will collect single-cell(-nuc) transcriptomic and epigenetic data from neuronal, glial, or vascular cells using MCI autopsy brains. Next, applicants will propose a data coordination center to collect single-cell(-nuc) omics data generated using diverse tissue sources and various, well-documented tissue preparation techniques from each group in the consortium. This data will be used to identify critical factors for robust and accurate single-cell(-nuc) omics analysis. Finally, this FOA will prompt applicants to coordinate their single-cell(-nuc) data sets with those produced by the BRAIN Initiatives human cell census. The aim is to enable investigators to utilize BRAIN cell census data sets generated from the analysis of healthy human brain and harmonize single-cell(-nuc) data sets from ADRD human brains with the BRAIN Initiative cell type registry.
Notice NOT-HS-21-020 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-22-027 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support pilot, feasibility or exploratory research in 5 priority areas in substance use epidemiology and health services, including: 1) responses to sudden and severe emerging drug issues (e.g. the ability to look into a large and sudden spike in opioid or synthetic cannabinoid use/overdoses in a particular community); 2) responses to emerging marijuana trends and topics related to the shifting policy landscape; 3) responses to unexpected and time-sensitive prescription drug abuse research opportunities (e.g., new state or local efforts); 4) responses to unexpected and time-sensitive medical system issues (e.g. opportunities to understand addiction services in the evolving health care system); and 5) responses to unexpected and time-sensitive criminal or juvenile justice opportunities (e.g. new system and/or structural level changes) that relate to drug abuse and access and provision of health care service. It should be clear that the knowledge gained from the proposed study is time-sensitive and that an expedited rapid review and funding are required in order for the scientific question to be answered (i.e. an imminent policy change will not allow for standard review and funding timeline).
Funding Opportunity RFA-DK-21-502 from the NIH Guide for Grants and Contracts. The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) was established in July 2002 for the purpose of identifying genetic variation predisposing to Inflammatory Bowel Disease (IBD). Since its establishment and in collaboration with the International IBD Genetics Consortium, the NIDDK IBDGC has identified over 250 IBD susceptibility loci. However, for the great majority of these loci, the specific causal variants and effector genes have not yet been identified, and the biological mechanisms through which these variants influence IBD pathophysiology remain to be elucidated. The purpose of this FOA is to renew the IBDGC with a continued mission to characterize the genetic architecture of IBD and its sub-phenotypes, particularly in populations currently under-represented in IBD genomic studies, and to elucidate the biological mechanisms by which genetic variants influence IBD pathophysiology, phenotypes and outcomes, with the long-term goal of improving disease course prediction and treatment. The Data Coordinating Center (DCC) of the IBDGC will coordinate collaboration among the Genetic Research Centers (GRCs, described in the companion FOA RFA-DK-21-022), enrollment of subjects into the study, submission of DNA and other biological samples to centralized repositories, processing of blood samples for extraction of DNA and isolation of other components, submission of clinical, genetic and molecular data to central databases, and data analysis. The DCC will manage the operations of the IBDGC Steering Committee and other operational committees and coordinate the collaboration of the NIDDK IBDGC with the International IBDGC, and with other external investigators conducting ancillary studies. The DCC will also coordinate the development of pilot projects for rapid follow-up of emerging findings by members of the IBDGC and external collaborators.